Arginine residues at the active site of avian liver phosphoenolpyruvate carboxykinase.
The presence of arginine at the active site of avian liver phosphoenolpyruvate carboxykinase was studied by chemical modification followed by a characterization of the modified enzyme. The arginine-specific reagents phenylglyoxal, 2,3-butanedione, and 1,2-cyclohexanedione all irreversibly inhibit the enzyme with second-order rate constants of 3.42 M-1 min-1, 3.13 M-1 min-1 and 0.313 M-1 min-1, respectively. The substrates phosphoenolpyruvate, IDP, and the activator Mn2+ offer little to modest protection from inhibition. Either CO2 or CO2 in the presence of any of the other substrates elicited potent protection against modification. Protection by CO2 against modification by phenylglyoxal or 1,2-cyclohexanedione gave a biphasic pattern. Rapid loss in activity to 40-60% occurred, followed by a very slow loss. Kinetics of inhibition suggest that the modification of arginine is specific and leads to loss of enzymatic activity. Substrate protection studies indicate an arginine residue(s) at the CO2 site of phosphoenolpyruvate carboxykinase. Apparently no arginine residues are at the binding site of the phosphate-containing substrates. Partially inactive (40-60% activity) enzyme, formed in the presence of CO2, has a slight change of its kinetic constants, and no alteration of its binding parameters or secondary structure as demonstrated by kinetic, proton relaxation rate, and circular dichroism studies. Labeling of enzyme with [(7-)14C]phenylglyoxal in the presence of CO2 (40-60% activity) showed 2 mol of phenylglyoxal/enzyme or 1 arginine or cysteine residue modified. Labeling of phosphoenolpyruvate carboxykinase in the absence of CO2 yielded 6 mol of label/enzyme. Labeling results indicate that avian phosphoenolpyruvate carboxykinase has 2 or 3 reactive arginine residues out of a total of 52 and only 1 or 2 are located at the active site and are involved in CO2 binding and activation.
Cheng
K C
KC
Department of Chemistry, University of Notre Dame, Indiana 46556.
Nowak
T
T
D000818:Animals; D001120:Arginine; D001665:Binding Sites; D002245:Carbon Dioxide / Q000494:pharmacology; D055598:Chemical Phenomena; D002621:Chemistry; D002645:Chickens; D002942:Circular Dichroism; D003512:Cyclohexanones / Q000494:pharmacology; D003931:Diacetyl / Q000494:pharmacology; D004578:Electron Spin Resonance Spectroscopy; D007290:Inosine Diphosphate / Q000494:pharmacology; D007700:Kinetics; D008099:Liver / Q000201:enzymology*; D008345:Manganese / Q000378:metabolism / Q000494:pharmacology; D010658:Phenylglyoxal / Q000378:metabolism / Q000494:pharmacology; D010728:Phosphoenolpyruvate / Q000494:pharmacology; D010729:Phosphoenolpyruvate Carboxykinase (GTP) / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011487:Protein Conformation
D003512:Cyclohexanones; D002245:Carbon Dioxide; D008345:Manganese; D010728:Phosphoenolpyruvate; C018031:1,2-cyclohexanedione; D007290:Inosine Diphosphate; D001120:Arginine; D010729:Phosphoenolpyruvate Carboxykinase (GTP); D003931:Diacetyl; D010658:Phenylglyoxal